Doctors have figured out a way to use herpes to fight untreatable advanced cancer
Roughly two-thirds of the global population has been infected with herpes simplex virus type 1 (HSV-1), which typically causes painful and unsightly blisters around the mouth.
University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically modifying HSV-1 and administering it to patients with treatment-resistant, advanced skin cancer along with an anti-cancer medication.
4 About 3.8 billion people worldwide have been infected with herpes simplex virus type 1 (HSV-1), which typically causes painful and unsightly blisters around the mouth.
and.one – stock.adobe.com
In a recent clinical trial, this one-two punch shrank tumors by at least 30% in around one-third of the 140 participants. Nearly one in six saw their tumors completely disappear.
'These findings are very encouraging because melanoma is the fifth most common cancer for adults, and about half of all advanced melanoma cases cannot be managed with currently available immunotherapy treatments,' said Dr. Gino Kim In, a medical oncologist with Keck Medicine of USC.
Advanced melanoma means the skin cancer has spread from its initial location to other parts of the body, such as lymph nodes, the liver or the brain.
Immunotherapy to help the immune system attack cancer cells, targeted therapy and radiation therapy are common treatment options.
4 This is a close-up of the herpes virus, which may hold the key in the battle against advanced melanoma.
BSIP/Universal Images Group via Getty Images
'The survival rate of untreatable advanced melanoma is only a few years, so this new therapy offers hope to patients who may have run out of options to fight the cancer,' In said.
In January, the Food and Drug Administration granted priority review to RP1 (the genetically modified HSV-1) with the anti-cancer medication nivolumab (marketed as Opdivo) for advanced melanoma patients whose cancer had not responded to immunotherapy.
Nivolumab blocks a key protein that cancer cells use to evade the immune system, paving the way for the immune system to recognize and attack these cells.
The idea is that nivolumab would enhance the effects of RP1, which targets, infects and replicates in tumor cells to destroy them — while sparing healthy tissue.
In told The Post that RP1 was developed by knocking out specific genes in HSV-1 so that it no longer causes cold sores.
'Additional genetic modifications were made to the virus to stimulate the immune system to better fight the cancer and to help the virus more efficiently interact with and kill tumor cells,' In said.
4 Nivolumab blocks a key protein that cancer cells use to evade the immune system, paving the way for the immune system to recognize and attack these cells.
luchschenF – stock.adobe.com
In the USC trial, researchers injected RP1 into superficial tumors on or near the skin's surface and into tumors deeper in the body, like in the liver or lungs.
We're Tracking Prime Day Live!
Unlock exclusive NYP codes and real-time deals on everyday must-haves. See Your Deals
The combination therapy was administered every two weeks for up to eight cycles.
Afterwards, the patients who started to see results took just nivolumab every four weeks for up to two years.
Researchers were stunned to notice a difference in the size of the treated and untreated tumors. The untouched tumors shrank or disappeared as often as the injected ones.
'This result suggests that RPI is effective in targeting cancer throughout the entire body and not just the injected tumor,' said In, 'which expands the potential effectiveness of the drug because some tumors may be more difficult or impossible to reach.'
4 Dr. Gino Kim In, a medical oncologist with Keck Medicine of USC, is one of the lead investigators on the trial.
Keck Medicine of USC
RP1 was reported to be well-tolerated among the participants.
Results from the trial were published Tuesday in the Journal of Clinical Oncology and recently presented at the American Society of Clinical Oncology annual meeting.
In and his team launched a phase 3 trial to study the effects of this treatment in over 400 cancer patients.
People interested in participating in the trial, sponsored by RP1 manufacturer Replimune, should contact Sandy Tran at sandy.tran@med.usc.edu.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
20 hours ago
- USA Today
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1) related anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, setting it apart from earlier CB1-targeting drugs that were discontinued due to serious central nervous system (CNS) effects. SKNY-1 is being developed as a potential oral treatment for obesity and addiction. It has previously been shown to achieve up to 30% weight loss, reverse high-calorie food and nicotine cravings, and preserve muscle mass in preclinical models. These new findings suggest that SKNY-1 may deliver these therapeutic effects without emotional or behavioral disruption, an important factor in long-term treatment adherence. 'These findings are a significant step forward,' said Erez Aminov, Chief Executive Officer of MIRA. 'The ability to suppress appetite and cravings while reversing anxiety-like effects is critical. These results reinforce the differentiated approach behind SKNY-1 and its potential role as a novel oral treatment in large, underserved markets.' About the Study The study used the light-dark preference test in zebrafish-a validated behavioral model to assess anxiety-related responses. Zebrafish naturally prefer darker environments due to an innate fear of predators. However, when anxiety levels are elevated, they avoid the light even more strongly spending more time in the dark. Reduced dark preference (i.e., more time in the light) is interpreted as a calming effect. Four groups were evaluated: Control Group (No Drug): Fish showed balanced behavior between light and dark environments. CP55,940 Group (CB1 Agonist): These animals spent significantly more time in the dark, confirming that CB1 activation increases anxiety at higher doses. Interestingly, at lower doses, CP55,940 produced a calming effect-reducing dark preference and encouraging exploration of the light area. Rimonabant Group (CB1 Inverse Agonist): Fish treated with Rimonabant also showed increased dark-zone time and exhibited a greater increase in anxiety-like behavior than the CB1 agonist group, under both high and low doses of agonist-consistent with the known psychiatric effects that led to Rimonabant's market withdrawal. SKNY-1 Groups: In animals co-treated with CP55,940, SKNY-1 significantly reversed the anxiety-inducing effects of high-dose CP55,940 and enhanced the calming effects at low doses. In all conditions, SKNY-1 brought anxiety-like behavior back to control or better-than-control levels. These results suggest SKNY-1 may help stabilize mood and stress-related behavior-a potential advantage in treating both metabolic and addictive disorders. A New Approach to Endocannabinoid Modulation SKNY-1 targets the endocannabinoid system (ECS)-a key regulator of hunger, emotion, reward, and addictive behavior-through a multi-pathway approach: Biased CB1 antagonism blocks β-arrestin signaling (linked to cravings and compulsive behavior) while preserving G-protein signaling (important for emotional regulation). CB2 partial agonism may reduce inflammation in the brain, which is increasingly recognized as a driver of anxiety, depression, and cognitive decline. By lowering neuroinflammation, SKNY-1 may help preserve emotional balance and support cognitive resilience. Mild inhibition of MAO-B regulates dopamine, which plays a role in motivation and behavioral control. No inhibition of MAO-A confirmed through in vitro screening-important because MAO-A inhibitors are associated with mood instability, drug interactions, and safety concerns. This multi-target profile gives SKNY-1 a differentiated mechanism that may allow it to reduce cravings and weight while supporting emotional health-without the psychiatric side effects that limited earlier CB1 or MAO-based drugs. 'The ability to block cravings while preserving emotional balance is a key challenge in this field,' said Dr. Itzchak Angel, MIRA's Chief Scientific Advisor. 'SKNY-1 appears to meet that challenge head-on. The demonstration that its profile is significantly different than rimonabant in its interaction with CB1 agonists, reinforces the unique pharmacological profile of the drug.' Market Opportunity Obesity and addiction are among the most urgent and expensive public health challenges globally. In the U.S. alone, the economic burden of obesity and related chronic diseases is estimated at $1.7 trillion annually, equivalent to over 9% of the nation's GDP (Milken Institute, 2023). Yet despite significant commercial investment, current therapies remain limited by efficacy gaps and tolerability challenges. Current GLP‑1 therapies like semaglutide deliver weight loss but are injectables, often cause gastrointestinal side effects, and can result in loss of lean muscle mass. Smoking cessation therapies such as varenicline or bupropion offer modest long-term success and may carry psychiatric warnings that restrict their use in sensitive patient populations. Earlier CB1-targeting drugs, including rimonabant, were withdrawn due to severe mood disorders. Furthermore, broad MAO inhibition-especially MAO‑A-has long been associated with mood instability and dangerous food-drug interactions. SKNY‑1 was developed to address those limitations directly. With oral administration, differentiated pharmacology, and potential dual efficacy in obesity and nicotine addiction, SKNY‑1 may offer a best-in-class profile. Its lack of MAO‑A inhibition, confirmed in vitro, further enhances its therapeutic promise. Next Steps MIRA is currently preparing for shareholder approval related to the proposed acquisition of SKNY Pharmaceuticals, Inc. Pending approval, the Company expects to initiate Investigational New Drug (IND)-enabling studies for SKNY-1 as a next step toward human clinical trials. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Helga Moya info@ (786) 432-9792 SOURCE: MIRA Pharmaceuticals View the original press release on ACCESS Newswire
Business Upturn
a day ago
- Business Upturn
Ozzi Launches Natural Drink to Help Stop Nighttime Cravings
Austin, TX, July 10, 2025 (GLOBE NEWSWIRE) — Ozzi , a new wellness brand focused on behavior-based nutrition, has officially launched its first product: a natural drink formulated to support evening appetite control. Designed as a GLP-1 alternative, the product offers a non-prescription option for adults seeking to manage stress-related snacking, particularly in the hours after work. Ozzi's crave-crushing drink sticks, formulated with fiber, allulose, and a natural GLP-1 boost. The formula contains 500mg of konjac root, 8g of allulose, African mango extract, Chromax, and BIOMEnd, combining these ingredients into a light, functional beverage intended for consumption around 8 pm. The product is caffeine-free, making it suitable for nighttime use without disrupting sleep. The idea for Ozzi originated from founder Brandon Kuipers' personal experience with evening stress-eating. 'I wanted something that would help me pause before reaching for snacks at night, something I could rely on without going the pharmaceutical route,' said Kuipers. After experimenting with natural ingredients and receiving feedback from early testers, the formula was finalized and moved into small-batch production. Customer testing played a central role in validating the product's appeal. When supply chain delays briefly interrupted fulfillment during the initial pilot, users were offered refunds. Instead, the majority chose to wait for restocks, reinforcing confidence in both the formulation and the unmet need it addresses. Ozzi is positioned as a wellness solution for busy professionals who experience cravings tied to long workdays and high stress levels. By targeting appetite control in the evening, the drink supports habit-building without relying on stimulants or prescription medication. The product is now available for purchase at , with nationwide shipping across the United States. All purchases include clear labeling, ingredient transparency, and guidance for use as part of a broader evening routine. About Ozzi Based in Austin, Texas, Ozzi is a consumer health brand focused on supporting mindful eating through accessible, science-backed products. The company emphasizes behavioral support and natural formulations designed for specific times of day. Ozzi's mission is to provide effective, practical tools for modern adults seeking healthier habits. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Boston Globe
2 days ago
- Boston Globe
What long COVID can teach us about future pandemics
Researchers are improving our understanding of the biological causes of long covid and working toward treatments. These advances may help not only people facing chronic illnesses today but also postinfection syndromes of the future. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up But experts are worried that despite the hard-won lessons of covid, we are not fully prepared for the next pandemic and its aftermath due to decreases in research funding and support, and polarization of public health measures. Advertisement Climate change and increasing human encroachment into wildlife habitats mean a higher risk of diseases spreading. " I would argue that probably we're less prepared for this now than we were even prepared for the covid-19 pandemic," Al-Aly said. Long covid is new and not new Long covid originally surprised researchers and clinicians, but in retrospect, there were clues that infections could lead to chronic health conditions in some patients, researchers said. Other illnesses and pandemics have caused post-acute infection syndromes that bear striking similarities to those of long covid. Advertisement Therefore, long covid is new and very much not new. Related : We now know that 'we have post-infectious disease syndromes that occur, and that it's not unique to covid, but covid really brought it to the forefront,' said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota. During and after the 1918 flu pandemic, people complained of feeling lethargic, memory problems and hazy thinking - which sounds a lot like the 'brain fog' and other neurocognitive effects of long covid. Farmers couldn't tend to their crops or shear their sheep, leading to economic distress. Years after the flu subsided, there was a rise in a Parkinson's-like symptoms tied to the illness. There was also a coinciding epidemic of encephalitis lethargica, or sleeping sickness, that some believe to be related to the flu, though this link is disputed. Similar long-lasting symptoms followed outbreaks of the respiratory viruses SARS-CoV-1 and Middle East respiratory syndrome (MERS) in the decades before covid. Some people also face persistent symptoms following Lyme disease, Ebola and dengue. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a still-mysterious chronic condition marked by persistent fatigue and malaise after exertion, is also suspected of having similar underlying causes as long covid; a 2024 meta-analysis found approximately half of long covid patients have ME/CFS. The difference with covid, of course, is 'just the sheer volume of people who had covid and got long covid,' which made it much easier to study and research compared with the other post-acute syndromes, said Wes Ely, a professor of medicine and co-director of the Center for Critical Illness, Brain Dysfunction, and Survivorship at Vanderbilt University Medical Center. Advertisement The pattern is now more apparent: While many people escape unscathed, 'it's clear that there's a wave of chronic disease and disability after pandemics,' Al-Aly said. A nurse recorded a patient's vitals. Long covid originally surprised researchers and clinicians, but in retrospect, there were clues that infections could lead to chronic health conditions. Kate Dearman/for The Washington Post This should factor into preparing for future pandemics and their aftereffects. 'We need to think about both the short and long term from the get-go when designing antivirals, designing vaccines' and identifying patients early to get them help earlier, Al-Aly said. Preparing for the aftermath of future pandemics In many ways, the United States may be less prepared to deal with the long covids of tomorrow than you would think. Understanding the biological causes of long covid will help. 'Investing in an understanding or unlocking the secrets of long covid' is going to pay dividends not only for long covid, but could be repurposed more broadly for post-viral illnesses of the present and future, Al-Aly said. But now, many of those resources and investments are at risk. Related : The Office of Long COVID Research and Practice, established in 2023 at the Department of Health and Human Services to coordinate the sprawling research efforts about the condition, has been shuttered. The HHS Secretary's Advisory Committee on Long Covid - a group of long covid physicians, researchers, patients and their advocates meant to advise on gaps in knowledge and research priorities - was terminated before its first meeting. Though HHS Secretary Robert F. Kennedy Jr. has stated his commitment to finding long covid treatments, citing long covid's impact on his son, there had not been any new structures put in place for long covid research as of June. Meanwhile, clinical trials searching for long covid treatments are continuing, but researchers fear that future funding may be at risk, following cuts to dozens of long covid research grants (some of which were later restored). Advertisement The Trump administration's budget proposal 'I think we have a lot of work to do. And, you know, it's terribly unfortunate so much of this work has been now stopped by this administration,' Osterholm said. However, the multibillion-dollar RECOVER Covid Initiative launched by the NIH allowed researchers to set up clinics and study long covid at a 'much bigger scale than they ever have been before,' said Leora Horwitz, a professor of population health and medicine at the New York University School of Medicine. 'I think they've put us in a good position now to recognize similar sorts of conditions of future as-yet-unknown pandemics.' The infrastructure set up by RECOVER has allowed for the long-term tracking of in-depth health data and could be a model for what to test in future pandemics, said Horwitz, who co-leads the branch of RECOVER studying adult patients, which includes almost 15,000 participants at 83 sites across 33 states. More important, there is now broader recognition that a subset of people can develop prolonged symptoms from infections, Horwitz said. Moen viewed imaging of mice brain sections that have been infected, and then treated, with SARS-CoV-2, at the Iwasaki Lab. Jackie Molloy/For the Washington Post Experts said that many of these developments and understanding were driven by fierce advocacy from the community of long covid patients, who have prompted politicians to act. However, the U.S. health care system remains strained even without contending with another pandemic, said Osterholm, who pointed to a projected shortage of physicians and other health care professionals. Advertisement Fixing the health care system is important, he said. 'If we don't invest right now, the bottom line is we're going to just do a repeat all over again in the next pandemic,' Osterholm said. At the same time, many of the public health tools for mitigating infection spread and severity - and therefore risk of long-term symptoms - have become increasingly politicized. Masking, vaccination, antivirals and improved indoor air quality have all helped combat covid and are valuable tools to implement should another pandemic arise, Al-Aly said. But people are increasingly tuning out these public health conversations and resisting being reminded of the pandemic, 'like almost collective amnesia,' he said. 'We paid a heavy price for this knowledge, and literally more than 1.1 million people died' in the United States, Al-Aly said. Now it's a 'question of whether there will be the political will and also the public sentiment to actually utilize this information for public good,' he said.
